Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 4Carcinoma 4Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Ras-mutated Metastatic Colorectal Cancer 1Osteosarcoma 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Glioma 1Glioblastoma 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Anal Cancer Metastatic 1Adenocarcinoma 1

Interventions

Pemetrexed 3mifamurtide 2lenvatinib 2dostarlimab 2belinostat 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2vactosertib 1surufatinib 1sintilimab 1robatumumab 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1omburtamab I-131 1niraparib 1isophosphamide mustard 1fludarabine 1endostar protein 1dinutuximab 1copanlisib 1cc-486 1cabozantinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Osteosarcoma × reolysin × Clear all
NCT00503295 2014-10-02

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Oncolytics Biotech

Phase 2 Completed
53 enrolled
Sarcoma

Fibrosarcoma, Leiomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡